When one plus one equals more than two.

当一加一大于二时。

• 批准号: 8851458
• 负责人: janice C Froehlich
• 金额: $ 30.26万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-10 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8851458
• 关键词: Acute; Address; Adverse effects; Agonist; Alcohol abuse; Alcohol consumption; Alcohol dependence; Alcoholic beverage heavy drinker; Alcoholism; Alcohols; Animal Model; Brain; Breeding; Clinical Research; Clinical Treatment; Communities; Consumption; Data; Development; Disease; Disulfiram; Drug Delivery Systems; Drug usage; Effectiveness; FDA approved; Goals; Health; Heavy Drinking; Human; Individual; Laboratories; Lead; Mediating; Methods; Naltrexone; National Institute on Alcohol Abuse and Alcoholism; Opioid; Opioid Receptor; Oral; Pharmaceutical Preparations; Play; Property; Rattus; Records; Relapse; Research; Research Design; Rewards; Rodent; Role; Stress; System; Testing; Time; Translations; United States National Institutes of Health; Work; acamprosate; alcohol abuse therapy; alcohol relapse; base; bench to bedside; compliance behavior; dependence relapse; deprivation; drinking; drug efficacy; effective therapy; innovation; pre-clinical; preference; problem drinker; receptor; smoking cessation; varenicline

DESCRIPTION (provided by applicant): Alcoholism is the most prevalent and widespread of all addictive diseases and development of effective treatments is a world-wide priority. Only three drugs have been approved by the FDA for the treatment of alcohol dependence: disulfiram (antibuse), acamprosate, and naltrexone (Trexan or Revia) and, of these, naltrexone (NTX) is the most effective. Yet NTX is under- utilized in clinical treatment settings because the efficacy of NTX is modest, it is not effective for all alcoholics and, when it is effective, a significant number of alcoholics fail to maintain initial treatment gains and subsequently relapse to heavy drinking. There is a pressing need for additional medications to treat alcohol abuse, dependence and relapse. The long-term objective of this proposal is to increase the number of drugs available to treat alcohol abuse and alcoholism. Both the opioid and acetylcholinergic systems in the brain play important roles in mediating alcohol drinking. Our preliminary studies indicate that acute oral treatment with either naltrexone (NTX), a nonspecific opioid receptor antagonist, or varenicline (V), an ¿4¿2 nicotinic acetylcholinergic receptor partial agonist, decreases alcohol intake in alcohol-preferring (P) rats that have been selectively bred for high voluntary alcohol drinking. The question now is whether these two drugs are effective over the course of prolonged treatment, and whether combining these two drugs into a single oral medication enhances the effectiveness, or prolongs the duration of action, of the combination when compared with either drug alone. The research design uses a voluntary oral drug consumption method that we developed which allows us to assess the efficacy of drugs over long periods of time. Our hypothesis is that NTX and V will act either additively or synergisticall to more effectively reduce alcohol drinking than can either drug alone. The specific aims of this proposal are to determine whether a combination of NTX + V is more effective than is either drug alone: 1) in decreasing ongoing alcohol drinking in rats selectively bred for alcohol preference and high alcohol intake (P rats), 2) in blocking the initiation/acquisition of alcohol drinking in P rats and 3) in blocking the increase in alcohol drinking that occurs following reaccess to alcohol following alcohol deprivation (alcohol deprivation effect of ADE, an animal model of alcohol relapse) in P rats. Mechanistic studies will determine whether NTX + V alters the rewarding/reinforcing properties of alcohol and/or alcohol clearance [[or drinking-induced BACs]]. The significance of the proposed work is that the results may lead to a new pharmacotherapeutic approach to the treatment of alcohol abuse, alcohol dependence and relapse; an approach that may be particularly valuable for treating alcoholics who do not respond to treatment with the medications currently available.

描述（由申请人提供）：酒精中毒是所有成瘾性疾病中最普遍和最普遍的，开发有效的治疗方法是世界范围内的优先事项。只有三种药物已被FDA批准用于治疗酒精依赖：双硫仑（antibuse），阿坎酸和纳洛酮（Trexan或Revia），其中纳洛酮（NTX）是最有效的。然而，NTX在临床治疗环境中的使用不足，因为NTX的功效是适度的，它不是对所有酗酒者有效，并且当它有效时，大量酗酒者不能保持最初的治疗增益，并且随后复发到大量饮酒。迫切需要更多的药物来治疗酒精滥用、依赖和复发。该提案的长期目标是增加治疗酗酒和酒精中毒的药物数量。大脑中的阿片和乙酰胆碱能系统在介导饮酒中起重要作用。我们的初步研究表明，急性口服治疗纳洛酮（NTX），非特异性阿片受体拮抗剂，或伐尼克兰（V），<$4 <$2烟碱乙酰胆碱能受体部分激动剂，减少酒精偏好（P）大鼠的酒精摄入量，这些大鼠被选择性地饲养为高自愿饮酒。现在的问题是，这两种药物在长期治疗过程中是否有效，以及与单独使用任何一种药物相比，将这两种药物合并为单一口服药物是否会增强有效性或延长作用时间。研究设计使用我们开发的自愿口服药物消耗方法，使我们能够评估药物在长时间内的疗效。我们的假设是，NTX和V将发挥相加或协同作用，以更有效地减少饮酒比单独使用任何一种药物。该提案的具体目的是确定NTX + V的组合是否比单独使用任何一种药物更有效：1）在选择性饲养的酒精偏好和高酒精摄入的大鼠中减少持续饮酒（P大鼠），2）在P大鼠中阻断饮酒的起始/获得，以及3）阻断P大鼠在酒精剥夺后重新获得酒精后发生的饮酒增加（ADE的酒精剥夺效应，酒精复发的动物模型）。机制研究将确定NTX + V是否会改变酒精和/或酒精清除[[或饮酒诱导的BAC]]的奖励/强化特性。拟议的工作的意义在于，结果可能导致一种新的药物治疗方法来治疗酒精滥用，酒精依赖和复发;这种方法可能对治疗目前可用药物治疗无效的酗酒者特别有价值。